Literature DB >> 34359840

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.

Caterina Cascini1, Claudia Chiodoni1.   

Abstract

Osteosarcoma (OS) is a high-grade malignant stromal tumor composed of mesenchymal cells producing osteoid and immature bone, with a peak of incidence in the second decade of life. Hence, although relatively rare, the social impact of this neoplasm is particularly relevant. Differently from carcinomas, molecular genetics and the role of the tumor microenvironment in the development and progression of OS are mainly unknown. Indeed, while the tumor microenvironment has been widely studied in other solid tumor types and its contribution to tumor progression has been definitely established, tumor-stroma interaction in OS has been quite neglected for years. Only recently have new insights been gained, also thanks to the availability of new technologies and bioinformatics tools. A better understanding of the cross-talk between the bone microenvironment, including immune and stromal cells, and OS will be key not only for a deeper knowledge of osteosarcoma pathophysiology, but also for the development of novel therapeutic strategies. In this review, we summarize the current knowledge about the tumor microenvironment in OS, mainly focusing on immune cells, discussing their role and implication for disease prognosis and treatment response.

Entities:  

Keywords:  bone marrow; macrophages; mesenchymal stem cells; osteoclasts; osteosarcoma; tumor microenvironment

Year:  2021        PMID: 34359840     DOI: 10.3390/cells10071668

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  8 in total

1.  Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation.

Authors:  Stefania Lama; Amalia Luce; Giuseppe Bitti; Pilar Chacon-Millan; Annalisa Itro; Pasquale Ferranti; Giovanni D'Auria; Marcella Cammarota; Giovanni Francesco Nicoletti; Giuseppe Andrea Ferraro; Chiara Schiraldi; Michele Caraglia; Evzen Amler; Paola Stiuso
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-08

2.  Baicalin induces apoptosis and autophagy in human osteosarcoma cells by increasing ROS to inhibit PI3K/Akt/mTOR, ERK1/2 and β-catenin signaling pathways.

Authors:  He Pang; Tingrui Wu; Zhonghua Peng; Qichao Tan; Xin Peng; Zeyu Zhan; Lijun Song; Bo Wei
Journal:  J Bone Oncol       Date:  2022-02-01       Impact factor: 4.491

3.  ATG16L1 is a Potential Prognostic Biomarker and Immune Signature for Osteosarcoma: A Study Based on Bulk RNA and Single-Cell RNA-Sequencing.

Authors:  Zhaojie Qin; Kai Luo; Wenyu Feng; Xinli Zhan; Yun Liu; Shijie Liao; Juliang He; Mingwei He; Tianyu Xie; Xiaohong Jiang; Boxiang Li; Huijiang Liu; Qian Huang; Haijun Tang
Journal:  Int J Gen Med       Date:  2022-02-02

4.  The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset.

Authors:  Weidong Liu; Yuedong Hao; Xiao Tian; Jing Jiang; Quanhe Qiu
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

5.  Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages.

Authors:  Elham Sajjadi; Gabriella Gaudioso; Andrea Terrasi; Francesca Boggio; Konstantinos Venetis; Mariia Ivanova; Letizia Bertolasi; Gianluca Lopez; Letterio Runza; Alice Premoli; Daniele Lorenzini; Elena Guerini-Rocco; Stefano Ferrero; Valentina Vaira; Nicola Fusco
Journal:  Front Mol Biosci       Date:  2022-08-26

6.  A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.

Authors:  Mingyi Yang; Haishi Zheng; Ke Xu; Qiling Yuan; Yirixaiti Aihaiti; Yongsong Cai; Peng Xu
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

7.  Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.

Authors:  Jianye Tan; Xuhui Feng; Hangxing Wu; Bingsheng Yang; Meiling Shi; Chao Xie; Zexin Su; Lin Li; Mengliang Luo; Zhijie Zuo; Shuang Zhu; Jiancheng Yang; Lijun Lin
Journal:  J Immunol Res       Date:  2022-08-27       Impact factor: 4.493

8.  A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.

Authors:  Runsang Pan; Feng Pan; Zhirui Zeng; Shan Lei; Yan Yang; Yushi Yang; Chujiao Hu; Houping Chen; Xiaobin Tian
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.